Association of the G473A Polymorphism and Expression of Lysyl Oxidase with Breast Cancer Risk and Survival in European Women: A Hospital-Based Case-Control Study
Figure 3
LOX expression in breast tumors and breast cancer cell lines.
Correlation of relative LOX expression (2−ΔΔCt values; y-axes) with LOX G473A genotype and with established clinical and histopathological parameters was analysed in breast cancer cell lines (A) and in breast tumors (B–L). All p-values were determined via unpaired, two-sided t-tests except in Ea. (A) Boxplot of LOX expression in breast cancer cell lines with the indicated G473A genotypes. Note the different range of the y-axis compared to B-L, and that log(2) expression values (−ΔΔCt values) are shown in A. (B) LOX expression in breast tumours from patients with the indicated G473A genotypes. A-carrier, patients with the AG (n = 17) and AA (n = 3) genotype. (C) LOX expression in patients with an age at breast cancer onset of <55 vs. ≥55 years. (D) LOX expression in pre- vs. post-menopausal patients. (E) LOX expression in paired tissue specimens of primary tumours vs. lymph node metastases (LN) of 17 patients. Accordingly, the indicated p-value of 0.002 was determined by paired, two-sided t-test. (F) LOX expression in breast tumours from patients with a negative (neg, pN0) vs. a positive (pos, pN+) lymph node status. (G) LOX expression in patients with the indicated tumor stages. Numbers in parentheses indicate the number of patients in each group. (H) LOX expression in pT1 vs. pT2–4 breast tumours. (I) LOX expression in estrogen receptor (ER) neg vs. pos tumours. (J) LOX expression in progesterone receptor (PR) neg vs. pos tumours. (K) LOX expression in HER2 neg vs. pos tumours. (L) LOX expression in p53 neg vs. pos tumours. ap-value was determined by paired, two-sided t-test in E; bp-value of an unpaired, two-sided t-test of stage I–II vs. stage III–IV patients is shown in G. LN, lymph node metastases; neg, negative; pos, positive.